- Afshar, Yalda;
- Dong, Jiantong;
- Zhao, Pan;
- Li, Lei;
- Wang, Shan;
- Zhang, Ryan Y;
- Zhang, Ceng;
- Yin, Ophelia;
- Han, Christina S;
- Einerson, Brett D;
- Gonzalez, Tania L;
- Zhang, Huirong;
- Zhou, Anqi;
- Yang, Zhuo;
- Chou, Shih-Jie;
- Sun, Na;
- Cheng, Ju;
- Zhu, Henan;
- Wang, Jing;
- Zhang, Tiffany X;
- Lee, Yi-Te;
- Wang, Jasmine J;
- Teng, Pai-Chi;
- Yang, Peng;
- Qi, Dongping;
- Zhao, Meiping;
- Sim, Myung-Shin;
- Zhe, Ruilian;
- Goldstein, Jeffrey D;
- Williams, John;
- Wang, Xietong;
- Zhang, Qingying;
- Platt, Lawrence D;
- Zou, Chang;
- Pisarska, Margareta D;
- Tseng, Hsian-Rong;
- Zhu, Yazhen
Placenta accreta spectrum (PAS) is a high-risk obstetrical condition associated with significant morbidity and mortality. Current clinical screening modalities for PAS are not always conclusive. Here, we report a nanostructure-embedded microchip that efficiently enriches both single and clustered circulating trophoblasts (cTBs) from maternal blood for detecting PAS. We discover a uniquely high prevalence of cTB-clusters in PAS and subsequently optimize the device to preserve the intactness of these clusters. Our feasibility study on the enumeration of cTBs and cTB-clusters from 168 pregnant women demonstrates excellent diagnostic performance for distinguishing PAS from non-PAS. A logistic regression model is constructed using a training cohort and then cross-validated and tested using an independent cohort. The combined cTB assay achieves an Area Under ROC Curve of 0.942 (throughout gestation) and 0.924 (early gestation) for distinguishing PAS from non-PAS. Our assay holds the potential to improve current diagnostic modalities for the early detection of PAS.